Navigation Links
Gynecologist disputes findings
Date:10/15/2010

(Phoenix, Arizona October 15, 2010) -- An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

Published in The Lancet last month, the study reported that women who received early chemotherapy for a recurrence of ovarian cancer did not live longer than those whose treatment is delayed. London-based, The Lancet is one of the world's most respected medical journals.

"While this study is a bold challenge to the assumption of early treatment, there are several significant problems with the findings," says Bradley Monk, MD, and a leader in developing new approaches to cancer treatments. "Our focus should no longer be on standard chemotherapy, but on targeted genetics-based treatments."

Dr. Monk expressed his concerns about the ovarian cancer study in an editorial in The Lancet. He and Dr. Robert Morris, of Wayne State University, wrote that finding the relevant therapy is far more important than timing when treating ovarian cancer. "The most troubling problem with the trial is that contemporary therapies were not available to most of the participants," says Dr. Monk. "This lack of availability is related not only to the chronological length of the trial (which started in 1996), but also to regulatory and financial barriers restricting access to all active compounds in the participating countries."

In the study, survival rates were not significantly different between those who started chemotherapy once a higher concentration of cancer-related proteins were detected and those whose treatment was delayed until they had clinical symptoms.

A total of 1,442 women from 59 centers around the world registered for the trial, and 529 were randomly assigned to treatment groups. About 70 percent of the women died. Of the 370 deaths, 186 occurred in the early treatment group and 184 in the delayed treatment. Median survival was 25.7 months for those on early treatment and 27.1 months for those on delayed treatment.


'/>"/>

Contact: Lynne Reaves
lynne.reaves@chw.edu
602-406-4734
St. Joseph's Hospital and Medical Center
Source:Eurekalert

Related biology news :

1. September 2007 Sumatran earthquakes research findings
2. Findings uncover new details about mysterious virus
3. Nearly a century later, new findings support Warburg theory of cancer
4. New research findings may enable earlier diagnosis of uterine cancer
5. Therapeutic cloning gets a boost with new research findings
6. International climate change researchers meet, review latest findings
7. Findings show insulin -- not genes -- linked to obesity
8. FANTOM findings boost for biologists
9. New findings in taste and smell
10. SRI International announces findings from new upper atmospheric radar system for scientific research
11. USC researchers present diabetes findings at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Driven by consumers, ... are now the fastest growing categories, finds the ... Actives in Personal Care: Multi-regional Market Analysis and ... management consulting firm Kline. "Biotechnology actives ... make them more effective for skin and hair ...
(Date:2/24/2017)... Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), the leading ... and production customers, today reported its financial results for the ... Highlights: 4Q16 record quarterly net ... on an organic basis. 4Q16 ... organic basis, while the Americas net sales increased 2.5%, or ...
(Date:2/23/2017)... Madison, Wisconsin (PRWEB) , ... February 23, 2017 ... ... their Drug Discovery Services portfolio to include an array of biochemical ... clients with reliable data to drive their hit-to-lead and SAR programs, including inhibitor ...
(Date:2/23/2017)... -- Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, parks and ... lice treatment salon to set up shop. But there,s ... French bistro on E Madison Ave, and CEO Maria ... lice clinic, we pride ourselves on being a destination for ... the stigma associated with lice. Everyone can get lice – ...
Breaking Biology Technology: